AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32046986 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based adherence monitoring
Number of subjects: 117
Study 32047009 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight-to-obese (OW) patients (BMI≥23kg/m²)
Number of subjects: 2021
Study 32047009 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight (NW) patients
Number of subjects: 2021
Study 32047009 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2021
Study 32047009 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2021
Study 32047009 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic health status
Number of subjects: 2021
Study 32047023 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced placement of fresh fruit and vegetables in intervention stores
Number of subjects: 1620
Study 32047073 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTES-R at 2 years
Number of subjects: 1177
Study 32047073 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTES-R at 3 years
Number of subjects: 1177
Study 32047073 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTES-R sensitivity
Number of subjects: 1177
Study 32047073 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTES-R in mild to moderate disease
Number of subjects: 1177
Study 32047073 — intervention group
Group type: EXPERIMENTAL
Intervention: CMTES-R in severe disease
Number of subjects: 1177
Study 32047648 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information technology platform intervention
Number of subjects: 0
Study 32047648 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-implementation)
Number of subjects: 0
Study 32047645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol supplementation (20,400 IU every other day)
Number of subjects: 53
Study 32047645 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cholecalciferol supplementation (400 IU every other day)
Number of subjects: 53
Study 32047671 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0
Study 32047671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32047722 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF + fingolimod
Number of subjects: 0
Study 32047825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopic surgery combined with a 3-month exercise program
Number of subjects: 150
Study 32047825 — intervention group
Group type: COMPARATOR
Intervention: 3-month exercise program alone
Number of subjects: 150
Study 32047825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopic surgery
Number of subjects: 150
Study 32047825 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic changes
Number of subjects: 150
Study 32047828 — intervention group
Group type: EXPERIMENTAL
Intervention: AGB/ITBR + RFMD
Number of subjects: 33
Study 32047828 — intervention group
Group type: COMPARATOR
Intervention: AGB/ITBR
Number of subjects: 33
Study 32047896 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic GVHD (cGVHD)
Number of subjects: 241
Study 32047896 — intervention group
Group type: EXPERIMENTAL
Intervention: Late acute GVHD (L-aGVHD)
Number of subjects: 241
Study 32047896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active L-aGVHD before day 114
Number of subjects: 241
Study 32047896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cGVHD
Number of subjects: 241
Study 32047896 — intervention group
Group type: COMPARATOR
Intervention: No cGVHD/L-aGVHD
Number of subjects: 241
Study 32047921 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR analysis of urine samples from vegans
Number of subjects: 118
Study 32047921 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR analysis of urine samples from omnivores
Number of subjects: 118
Study 32047921 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR analysis of urine samples for discrimination
Number of subjects: 118
Study 32048075 — intervention group
Group type: COMPARATOR
Intervention: Deprived patients (n=629)
Number of subjects: 1294
Study 32048075 — intervention group
Group type: COMPARATOR
Intervention: Non-deprived patients (n=665)
Number of subjects: 1294
Study 32048075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both deprived and non-deprived patients
Number of subjects: 1294
Study 32048179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol-rich cannabis extracts
Number of subjects: 29
Study 32048179 — intervention group
Group type: COMPARATOR
Intervention: Co-administration with zonisamide
Number of subjects: 29
Study 32048179 — intervention group
Group type: COMPARATOR
Intervention: Co-administration with levetiracetam
Number of subjects: 29
Study 32048312 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM)
Number of subjects: 19
Study 32048312 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive DHM feeding
Number of subjects: 19
Study 32048419 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) during perception of communicative gestures
Number of subjects: 18
Study 32048419 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) during perception of communicative speech
Number of subjects: 18
Study 32048419 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) during perception of noncommunicative gestures
Number of subjects: 18
Study 32048753 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trials with effective treatment for at least one month
Number of subjects: 81
Study 32048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 344
Study 32048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovered AN
Number of subjects: 344
Study 32048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 344
Study 32048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eating disorders not otherwise specified
Number of subjects: 344
Study 32048754 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 344
Study 32048786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 100
Study 32048808 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT) for childhood obesity, duration: 6 months
Number of subjects: 0
Study 32048808 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT) for childhood obesity, sessions 10 to 20
Number of subjects: 0
Study 32048889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose
Number of subjects: 0
Study 32049318 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α
Number of subjects: 0
Study 32049318 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFN treatment
Number of subjects: 0
Study 32049318 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of IL-12
Number of subjects: 0
Study 32049638 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour plasma glucose (2 h PG)
Number of subjects: 542
Study 32049638 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 542
Study 32049638 — intervention group
Group type: EXPERIMENTAL
Intervention: iIFG
Number of subjects: 542
Study 32049638 — intervention group
Group type: EXPERIMENTAL
Intervention: iIGT
Number of subjects: 542
Study 32049638 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal FPG with elevated TGs, hypertension, moderate-to-severe non-alcoholic fatty liver disease or MetS
Number of subjects: 542
Study 32049677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Disc Arthroplasty
Number of subjects: 0
Study 32049677 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Number of subjects: 0
Study 32049753 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Survey of Activities and Fear of Falling in the Elderly (SAFE-T)
Number of subjects: 111
Study 32049753 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE-T activity level
Number of subjects: 111
Study 32049753 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE-T activity restriction
Number of subjects: 111
Study 32049753 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE-T fear of falling subscale
Number of subjects: 111
Study 32049773 — intervention group
Group type: COMPARATOR
Intervention: Cohort A (no lopinavir/ritonavir resistance, stayed on second-line regimen)
Number of subjects: 545
Study 32049773 — intervention group
Group type: COMPARATOR
Intervention: Cohorts B, C, and D (increasing resistance, accessed novel ART regimens)
Number of subjects: 545
Study 32049773 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 545
Study 32050231 — intervention group
Group type: EXPERIMENTAL
Intervention: Presbyopic posterior chamber pIOL (IPCL) implantation
Number of subjects: 17
Study 32050447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised plus intravenous vancomycin; dosage and duration not specified
Number of subjects: 0
Study 32050447 — intervention group
Group type: COMPARATOR
Intervention: Control group; treatment not specified
Number of subjects: 0
Study 32050956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty (BT)
Number of subjects: 24
Study 32051148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 0
Study 32051148 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cardiovascular reflex tests
Number of subjects: 0
Study 32051219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-back envelope for opioid return
Number of subjects: 331
Study 32051222 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative quality improvement interventions (altered physician workflow, standardized discharge checklists, physician workshops)
Number of subjects: 0
Study 32051222 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32052016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Meal Test (MMT) in AAs
Number of subjects: 83
Study 32052016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic IDE activity in AAs
Number of subjects: 83
Study 32052016 — intervention group
Group type: COMPARATOR
Intervention: Hepatic IDE and CEACAM-1 levels
Number of subjects: 83
Study 32052264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 5 mg BID
Number of subjects: 450
Study 32052264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 mg BID
Number of subjects: 450
Study 32052264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg BID
Number of subjects: 450
Study 32052264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg BID
Number of subjects: 450
Study 32052264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 32052315 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-clopidogrel platelet reactivity (HPR)
Number of subjects: 121
Study 32052315 — intervention group
Group type: EXPERIMENTAL
Intervention: HPR and β-amyloid > 51 mg/dl
Number of subjects: 121
Study 32052315 — intervention group
Group type: EXPERIMENTAL
Intervention: HPR and MOTS-c < 167 ng/ml
Number of subjects: 121
Study 32052473 — intervention group
Group type: EXPERIMENTAL
Intervention: Urelumab alone (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W)
Number of subjects: 106
Study 32052473 — intervention group
Group type: EXPERIMENTAL
Intervention: Urelumab plus rituximab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W plus rituximab 375 mg/m2)
Number of subjects: 106
Study 32052523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone-treated RTR
Number of subjects: 693
Study 32052566 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased positive symptoms
Number of subjects: 404
Study 32052566 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased negative symptoms
Number of subjects: 404
Study 32052566 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased positive symptoms at baseline
Number of subjects: 404
Study 32052566 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression at baseline
Number of subjects: 404
Study 32053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive evaluations using the Consortium to Establish a Registry for Alzheimer's Disease Plus test battery.
Number of subjects: 200
Study 32053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measurement Information System Profile 29 and Hospital Anxiety and Depression Scale for assessing physical, mental, and social health.
Number of subjects: 200
Study 32053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale for screening postoperative delirium (POD).
Number of subjects: 200
Study 32053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, criteria for validation of POD.
Number of subjects: 200
Study 32053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of (neuro)inflammation including interleukins, C-reactive protein, tumor necrosis factor alpha.
Number of subjects: 200
Study 32053113 — intervention group
Group type: EXPERIMENTAL
Intervention: Reevaluation of cognitive abilities 3 months postoperatively to investigate presence of POCD.
Number of subjects: 200
Study 32053116 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric hotline consultation
Number of subjects: 0
Study 32053203 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical Treatment Interruption (ATI)
Number of subjects: 11
Study 32053612 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 1000 mg once daily for 12 months
Number of subjects: 10
Study 32053771 — intervention group
Group type: EXPERIMENTAL
Intervention: Celyvir (autologous MSCs carrying oncolytic adenovirus), administered intravenously, 2 × 10^9 cells weekly for 6 weeks
Number of subjects: 0
Study 32054150 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint blocker (ICB) therapy
Number of subjects: 127
Study 32054150 — intervention group
Group type: COMPARATOR
Intervention: Palliative radiotherapy (RT)
Number of subjects: 127
Study 32054467 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of soluble programmed death-ligand 1 (sPD-L1)
Number of subjects: 68
Study 32054467 — intervention group
Group type: COMPARATOR
Intervention: Low serum levels of soluble programmed death-ligand 1 (sPD-L1)
Number of subjects: 68
Study 32054467 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of IL-7
Number of subjects: 68
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Representatives (CHRs) involvement in the clinical team
Number of subjects: 13
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE coaching materials
Number of subjects: 13
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face COPE trainings with CHRs
Number of subjects: 13
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to electronic health records for CHRs
Number of subjects: 13
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests for designated personnel for referrals
Number of subjects: 13
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal system to record CHR training modules
Number of subjects: 13
Study 32054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of community health workers into clinic-based teams
Number of subjects: 13
Study 32054625 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) collected during a 1-year follow-up period.
Number of subjects: 3000
Study 32054625 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected from patient medical records and national compulsory registries.
Number of subjects: 3000
Study 32055239 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 24
Study 32055239 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms applied to 40 proteins
Number of subjects: 24
Study 32055404 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT)
Number of subjects: 0
Study 32055404 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study 32055787 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline preloading for 6 weeks
Number of subjects: 0
Study 32055787 — intervention group
Group type: COMPARATOR
Intervention: Standard varenicline preloading for 1 week
Number of subjects: 0
Study 32055790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (specific appointments for further examinations by quality-assured doctors at a designated local hospital)
Number of subjects: 9936
Study 32055790 — intervention group
Group type: COMPARATOR
Intervention: Control (free school-based eye screening, usual practice)
Number of subjects: 9936
Study 32055862 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine treatment
Number of subjects: 204
Study 32055862 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids pretreatment
Number of subjects: 204
Study 32055862 — intervention group
Group type: COMPARATOR
Intervention: Apheresis pretreatment
Number of subjects: 204
Study 32055965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study 32056017 — intervention group
Group type: EXPERIMENTAL
Intervention: STE-derived parameters
Number of subjects: 48
Study 32056537 — intervention group
Group type: EXPERIMENTAL
Intervention: SKIP intervention
Number of subjects: 33
Study 32056676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer plus a website with feedback, goal-setting, disease education, and a community forum
Number of subjects: 0
Study 32056676 — intervention group
Group type: COMPARATOR
Intervention: Pedometer alone (control)
Number of subjects: 0
Study 32056939 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious individuals
Number of subjects: 0
Study 32056939 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and older age
Number of subjects: 0
Study 32057467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240mg Q2W for 6 infusions and ipilimumab 1mg/kg Q6W for 2 infusions in neoadjuvant setting, followed by nivolumab 480mg Q4W for 9 infusions post-surgery.
Number of subjects: 32
Study 32057706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 206
Study 32057706 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography coronary angiography (CTA)
Number of subjects: 206
Study 32057706 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 206
Study 32058557 — intervention group
Group type: EXPERIMENTAL
Intervention: gFOLFIRINOX therapy (fluorouracil 2400 mg/m2 over 46 hours; oxaliplatin 85 mg/m2; irinotecan 180 mg/m2 for UGT1A1 genotype 6/6, 135 mg/m2 for 6/7, or 90 mg/m2 for 7/7; prophylactic peg-filgastrim 6 mg) for 4 cycles before and after surgery.
Number of subjects: 36
Study 32058557 — intervention group
Group type: EXPERIMENTAL
Intervention: gFOLFIRINOX therapy with trastuzumab for ERBB2-positive tumors.
Number of subjects: 36
Study 32058557 — intervention group
Group type: EXPERIMENTAL
Intervention: gFOLFIRINOX therapy (including trastuzumab for ERBB2-positive tumors)
Number of subjects: 36
Study 32058843 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) at recommended doses for expansion (5.4 or 6.4 mg/kg) administered intravenously once every 3 weeks
Number of subjects: 54
Study 32058843 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 54
Study 32058843 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg
Number of subjects: 54
Study 32058873 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to study-guideline (SG) for post-operative RT
Number of subjects: 848
Study 32058873 — intervention group
Group type: EXPERIMENTAL
Intervention: Less RT than predefined target volumes
Number of subjects: 848
Study 32058873 — intervention group
Group type: EXPERIMENTAL
Intervention: More extensive RT than according to SG
Number of subjects: 848
Study 32058873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk group adherence to SG
Number of subjects: 848
Study 32058873 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial deviation from SG for post-operative RT
Number of subjects: 848
Study 32059085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib added to arsenic trioxide (ATO)
Number of subjects: 22
Study 32059193 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified spine MRI protocol (3D sequences modified to 2D, reduced number of slices)
Number of subjects: 9
Study 32059193 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical spine MRI protocols
Number of subjects: 9
Study 32059615 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Verio Reflect blood glucose monitor
Number of subjects: 0
Study 32059714 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 48
Study 32059719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (382 patients)
Number of subjects: 971
Study 32059719 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (589 patients, 388 RYGB and 201 SG)
Number of subjects: 971
Study 32059719 — intervention group
Group type: COMPARATOR
Intervention: Control group (156 patients left the study without treatment)
Number of subjects: 971
Study 32059815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil intravenous lipid emulsion (FOLE) 1 g/kg/day
Number of subjects: 123
Study 32059815 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil intravenous lipid emulsion (SOLE) up to 3 g/kg/day
Number of subjects: 123
Study 32059815 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLE
Number of subjects: 123
Study 32059815 — intervention group
Group type: COMPARATOR
Intervention: SOLE
Number of subjects: 123
Study 32060053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously on day 1 and capecitabine 1000 mg/m²
Number of subjects: 30
Study 32060053 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 30
Study 32060062 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0